Earnings Call · Q3 FY2022·2022-11-07

Q3 22EPS +2.73%·Rev n/aQ2 22EPS +5.36%·Rev n/aQ1 22EPS -1.98%·Rev n/aQ4 21EPS +11.76%·Rev n/a⚠ consensus missing

Axsome Therapeutics, Inc. AXSM

Mark Jacobson — Investor Relations

Herriot Tabuteau — Chief Executive Officer

Nick Pizzie — Chief Financial Officer

Lori Englebert — Chief Commercial Officer

−0.5%1d on move date−1.4% vs SPY3d+3.4%5d+3.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AXSM calls or request research access.

More AXSM calls Browse calls Request research access